These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1828 related articles for article (PubMed ID: 19447418)

  • 1. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
    Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
    J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy.
    Lotan Y; Bagrodia A; Passoni N; Rachakonda V; Kapur P; Arriaga Y; Bolenz C; Margulis V; Raj GV; Sagalowsky AI; Shariat SF
    Eur Urol; 2013 Sep; 64(3):465-71. PubMed ID: 23571005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer.
    Shariat SF; Tokunaga H; Zhou J; Kim J; Ayala GE; Benedict WF; Lerner SP
    J Clin Oncol; 2004 Mar; 22(6):1014-24. PubMed ID: 14981102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer.
    Shariat SF; Chade DC; Karakiewicz PI; Ashfaq R; Isbarn H; Fradet Y; Bastian PJ; Nielsen ME; Capitanio U; Jeldres C; Montorsi F; Lerner SP; Sagalowsky AI; Cote RJ; Lotan Y
    J Urol; 2010 Jan; 183(1):68-75. PubMed ID: 19913255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.
    Bertz S; Otto W; Denzinger S; Wieland WF; Burger M; Stöhr R; Link S; Hofstädter F; Hartmann A
    Eur Urol; 2014 Jan; 65(1):218-26. PubMed ID: 22633802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers.
    Shariat SF; Youssef RF; Gupta A; Chade DC; Karakiewicz PI; Isbarn H; Jeldres C; Sagalowsky AI; Ashfaq R; Lotan Y
    J Urol; 2010 May; 183(5):1744-50. PubMed ID: 20299037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk stratification of organ confined bladder cancer after radical cystectomy using cell cycle related biomarkers.
    Shariat SF; Chromecki TF; Cha EK; Karakiewicz PI; Sun M; Fradet Y; Isbarn H; Scherr DS; Bastian PJ; Pummer K; Fajkovic H; Sagalowsky AI; Ashfaq R; Doblinger M; Cote RJ; Lotan Y
    J Urol; 2012 Feb; 187(2):457-62. PubMed ID: 22177145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective evaluation of a preoperative biomarker panel for prediction of upstaging at radical cystectomy.
    Shariat SF; Passoni N; Bagrodia A; Rachakonda V; Xylinas E; Robinson B; Kapur P; Sagalowsky AI; Lotan Y
    BJU Int; 2014 Jan; 113(1):70-6. PubMed ID: 24053584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy.
    Shariat SF; Karakiewicz PI; Ashfaq R; Lerner SP; Palapattu GS; Cote RJ; Sagalowsky AI; Lotan Y
    Cancer; 2008 Jan; 112(2):315-25. PubMed ID: 18008359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of american joint committee on cancer pathological stage T2a versus T2b urothelial carcinoma: analysis of patient outcomes in organ confined bladder cancer.
    Boudreaux KJ; Clark PE; Lowrance WT; Rumohr JA; Barocas DA; Cookson MS; Smith JA; Chang SS
    J Urol; 2009 Feb; 181(2):540-5; discussion 546. PubMed ID: 19084855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positive surgical margins in soft tissue following radical cystectomy for bladder cancer and cancer specific survival.
    Dotan ZA; Kavanagh K; Yossepowitch O; Kaag M; Olgac S; Donat M; Herr HW
    J Urol; 2007 Dec; 178(6):2308-12; discussion 2313. PubMed ID: 17936804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes after urothelial recurrence in bladder cancer patients undergoing radical cystectomy.
    Mitra AP; Alemozaffar M; Harris BN; Schuckman AK; Skinner EC; Daneshmand S
    Urology; 2014 Dec; 84(6):1420-6. PubMed ID: 25306479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphovascular invasion of urothelial cancer in matched transurethral bladder tumor resection and radical cystectomy specimens.
    Kunju LP; You L; Zhang Y; Daignault S; Montie JE; Lee CT
    J Urol; 2008 Nov; 180(5):1928-32; discussion 1932. PubMed ID: 18801529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphovascular invasion is independently associated with poor prognosis in patients with localized upper urinary tract urothelial carcinoma treated surgically.
    Saito K; Kawakami S; Fujii Y; Sakura M; Masuda H; Kihara K
    J Urol; 2007 Dec; 178(6):2291-6; discussion 2296. PubMed ID: 17936818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease.
    Margulis V; Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
    Clin Cancer Res; 2006 Dec; 12(24):7369-73. PubMed ID: 17189409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma.
    Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
    J Urol; 2007 Feb; 177(2):481-7; discussion 487. PubMed ID: 17222615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy.
    Lotan Y; Gupta A; Shariat SF; Palapattu GS; Vazina A; Karakiewicz PI; Bastian PJ; Rogers CG; Amiel G; Perotte P; Schoenberg MP; Lerner SP; Sagalowsky AI
    J Clin Oncol; 2005 Sep; 23(27):6533-9. PubMed ID: 16116151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining smoking information and molecular markers improves prognostication in patients with urothelial carcinoma of the bladder.
    Wang LC; Xylinas E; Kent MT; Kluth LA; Rink M; Jamzadeh A; Rieken M; Al Hussein Al Awamlh B; Trinh QD; Sun M; Karakiewicz PI; Novara G; Chrystal J; Zerbib M; Scherr DS; Lotan Y; Vickers A; Shariat SF
    Urol Oncol; 2014 May; 32(4):433-40. PubMed ID: 24433754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patients.
    Tilki D; Reich O; Svatek RS; Karakiewicz PI; Kassouf W; Novara G; Ficarra V; Chade DC; Fritsche HM; Gerwens N; Izawa JI; Lerner SP; Schoenberg M; Stief CG; Skinner E; Lotan Y; Sagalowsky AI; Shariat SF
    J Urol; 2010 May; 183(5):1757-63. PubMed ID: 20299059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach.
    Garcia del Muro X; Condom E; Vigués F; Castellsagué X; Figueras A; Muñoz J; Solá J; Soler T; Capellà G; Germà JR
    Cancer; 2004 May; 100(9):1859-67. PubMed ID: 15112266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 92.